AKT1 and neoplasm: MK-2206 (Akt variant non-ATP competitive inhibitor), an anticancer agent that inhibits all Akt subtypes, is commonly used to synergistically enhance the anti-tumor efficacy of certain molecular targeted drugs (Yap et al., 2011).